Work

Gene Therapy Prolongs PSA Doubling Time in Prostate Cancer Patients

Year: 2007

Type: article

Abstract: Over the last decade, the use of adenoviral vector-mediated gene therapy for prostate cancer has become the focus of many laboratory and clinical scientists. Protocols involving systemic injections of replication-competent adenovirus have been tested in preclinical studies and evaluated in clinical trials1 and reviewed in the literature.2, 3, 4 Although these approaches are important for direct targeting of metastatic disease, significant challenges remain for their successful application. Alternative approaches have involved intratumoral or in situ delivery of replication-competent or replication-defective adenoviral vectors.

Source: Molecular Therapy

DOI: 10.1038/sj.mt.6300085

Authors: Timothy C Thompson, Ron Rodriguez

Institutions: Baylor College of Medicine, Johns Hopkins University

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500